Idexx Laboratories
IDXX
1,109 hedge funds and large institutions have $36.4B invested in Idexx Laboratories in 2024 Q2 according to their latest regulatory filings, with 84 funds opening new positions, 420 increasing their positions, 386 reducing their positions, and 107 closing their positions.
3.2% more ownership
Funds ownership: 87.39% → 90.59% (+3.2%)
9% more repeat investments, than reductions
Existing positions increased: 420 | Existing positions reduced: 386
3% less funds holding
Funds holding: 1,148 → 1,109 (-39)
7% less capital invested
Capital invested by funds: $39.1B → $36.4B (-$2.69B)
21% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 107
28% less call options, than puts
Call options by funds: $108M | Put options by funds: $150M
36% less funds holding in top 10
Funds holding in top 10: 22 → 14 (-8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$612M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$499M |
| 3 |
BlackRock
New York
|
+$199M |
| 4 |
ClearBridge Investments
New York
|
+$155M |
| 5 |
Goldman Sachs
New York
|
+$113M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Amundi
Paris,
France
|
-$88.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$86.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$77.5M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$73.7M |
| 5 |
Select Equity Group
New York
|
-$63.5M |
IDXX Hedge Fund Activity: Q2 2024 in Review
1,109 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Idexx Laboratories (IDXX) for Q2 2024, worth a combined $36.4B — down 6.9% from $39.1B a quarter earlier.
Sellers outnumbered buyers: 107 funds closed out of IDXX and 84 opened new positions — a net loss of 23 holders — while 386 trimmed existing stakes and 420 added.
The largest buyer was Vanguard Group, adding an estimated $612M. The largest seller was Amundi, cutting an estimated $88.1M.
- 1,109 institutional investors held Idexx Laboratories (IDXX) as of Q2 2024, down from 1,148 in Q1 2024.
- Funds reported $36.4B of Idexx Laboratories stock for Q2 2024, down 6.9% quarter-over-quarter.
- 84 funds opened new Idexx Laboratories positions in Q2 2024 and 107 closed out, a net change of -23 holders.
- The largest Idexx Laboratories buyer in Q2 2024 was Vanguard Group, an estimated $612M added.
- The largest Idexx Laboratories seller in Q2 2024 was Amundi, an estimated $88.1M sold.
Based on aggregated 13F filings for Q2 2024.